THALES
8.10.2020 09:02:14 CEST | Business Wire | Press release
Thales today announced a new high-performance data security solution for Teradata customers using the Vantage platform for data and analytics. By providing users with a totally transparent and scalable encryption solution to protect data at rest in any environment, the Thales Transparent Encryption solutions enable Teradata Vantage customers to better meet compliance and privacy regulations through encryption, access controls and data access audit logging.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005043/en/
Easily deployed across files and systems, this solution enables data at rest to be quickly encrypted within the Vantage platform. Since it is “transparent”, it is simple to deploy because there are no application development or database integration changes required. The cost-effective solution removes data breach risks and supports compliance initiatives while saving organisations months on the deployment of data protection for a Teradata environment.
Effective Access Policy Management at Scale
Thales’ Transparent Encryption is completely invisible to Vantage users and administrators as long as they are authorised to access the databases and system files they won’t know that solution is protecting your business. However, processes and actions from unauthorised users are immediately stopped and logged. The solution can be flexibly deployed across physical, virtual and cloud environments, giving organisations the ability to implement granular access policies that allow administrators to access infrastructure and systems without ever being able to see sensitive data in clear text.
The solution is designed to meet the high-scale and performance requirements of Vantage deployments on-premises, in clouds and hybrid, which can be several hundred terabytes to many petabytes in size and contain highly sensitive and regulated data and subsequently subject to privacy regulations (e.g., GDPR, CCPA, etc.). The scalable solution provides little overhead, from encryption and decryption activities, letting users robustly secure data and retain critical I/O and storage efficiencies.
“We’re pleased to have worked with the Teradata team to expand the Thales offering to include the transparent encryption solutions for Teradata. Our existing joint customers will simply expand their data security platform investment to include their Vantage environment. They will find that the policies for encryption, privileged user access and the additional security intelligence logs to further enhance their visibility are entirely familiar. New customers will be taking their first steps in unifying all their data security requirements and use cases on one easy to use, scalable and high-performance platform. The Thales solution complements the rich set of controls in the Vantage environment, ensuring that deployments meet the toughest regulatory audit scrutiny and protects a company’s most valuable data,” said Todd Moore, Senior Vice President, Encryption Solutions at Thales .
Jay Irwin JD, Director of Teradata Center for Enterprise Security added: "Teradata’s customer base is comprised of some of the largest and most data-centric companies on the planet. Security at scale is vital to this clientele, which makes Thales’ solution a particularly good fit for enabling Teradata's best-in-industry cloud security to be even more robust. With the application of Thales transparent encryption solutions, we provide a layered defense that protects customer data on-premises, in the cloud and in hybrid environments – all deployment types that our customers use today.”
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019.
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.
PLEASE VISIT
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005043/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom